ORIC Pharmaceuticals names new chief scientific officer
10 July 2019 -

ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing cancer treatments that address mechanisms of therapeutic resistance, has named Lori Friedman, PhD as its new chief scientific officer, it was reported yesterday.

Dr Friedman will serve on the executive leadership team and lead ORIC's research and preclinical development efforts. She has more than 20 years of experience in cancer research, including expertise in cancer target discovery and validation, signal transduction, cancer genetics, drug discovery, pharmacology and biomarkers. During her 15-year career at Genentech, she held roles of increasing responsibility and was most recently head of translational oncology for Genentech Research and Early Development, where her team advanced more than 20 programs into clinical development. Dr Friedman also sat on multiple cross-functional leadership teams tasked with strategic and technical review of Genentech's oncology research pipeline projects. Prior to Genentech, Dr Friedman held various scientific leadership roles at Exelixis.

Jacob Chacko, MD, chief executive officer, said, 'We are thrilled to continue attracting top talent to ORIC's leadership team. Lori has a multi-decade record of leadership in oncology drug discovery and translation, including identifying and advancing multiple novel programs into the clinic that eventually achieved regulatory approval and commercialisation. Lori's scientific acumen, leadership abilities and ability to collaborate closely on clinical development plans will be critical to continuing to advance and expand ORIC's pipeline.'